Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor as a treatment for pain via a novel mechanisms different from conventional...
8 KB (645 words) - 02:39, 16 July 2024
provide long term relief or a permanent solution for patients. Currently, Tanezumab, a monoclonal antibody that suppresses nerve activity, has been in development...
60 KB (6,696 words) - 11:35, 23 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
165 KB (17,240 words) - 08:04, 14 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
173 KB (16,045 words) - 14:23, 2 September 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
118 KB (11,362 words) - 03:08, 29 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
142 KB (13,867 words) - 14:04, 30 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
96 KB (10,049 words) - 11:48, 26 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
117 KB (11,945 words) - 21:51, 30 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
123 KB (11,364 words) - 16:41, 28 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
39 KB (3,474 words) - 06:01, 27 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
222 KB (19,669 words) - 18:52, 20 August 2024
(PG110) ASP-6294 Fasinumab Frunevetmab Fulranumab MEDI-578 Ranevetmab Tanezumab Aptamers: Against NGF: RBM-004 Decoy receptors: LEVI-04 (p75NTR-Fc) PDGF...
31 KB (3,430 words) - 05:24, 28 August 2024
(PG110) ASP-6294 Fasinumab Frunevetmab Fulranumab MEDI-578 Ranevetmab Tanezumab Aptamers: Against NGF: RBM-004 Decoy receptors: LEVI-04 (p75NTR-Fc) PDGF...
121 KB (13,799 words) - 18:32, 22 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
60 KB (5,878 words) - 03:22, 2 September 2024
(PG110) ASP-6294 Fasinumab Frunevetmab Fulranumab MEDI-578 Ranevetmab Tanezumab Aptamers: Against NGF: RBM-004 Decoy receptors: LEVI-04 (p75NTR-Fc) PDGF...
149 KB (15,717 words) - 06:34, 13 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
124 KB (11,463 words) - 17:07, 23 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
59 KB (5,310 words) - 01:24, 27 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
59 KB (5,926 words) - 22:40, 29 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
152 KB (16,395 words) - 02:17, 2 September 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
53 KB (4,607 words) - 21:09, 15 July 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
236 KB (24,280 words) - 19:10, 2 September 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
44 KB (4,012 words) - 07:08, 27 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
80 KB (8,072 words) - 11:52, 24 July 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
31 KB (2,865 words) - 19:00, 14 August 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
10 KB (633 words) - 16:45, 9 July 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
32 KB (3,136 words) - 10:53, 18 May 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
22 KB (2,039 words) - 06:04, 14 July 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
123 KB (12,189 words) - 17:43, 1 September 2024
Ketamine Menthol Methoxyflurane Phenazopyridine Proglumide Rimazolium Tanezumab #WHO-EM ‡Withdrawn from market Clinical trials: †Phase III §Never to phase...
57 KB (5,575 words) - 13:25, 25 August 2024
(PG110) ASP-6294 Fasinumab Frunevetmab Fulranumab MEDI-578 Ranevetmab Tanezumab Aptamers: Against NGF: RBM-004 Decoy receptors: LEVI-04 (p75NTR-Fc) PDGF...
24 KB (1,710 words) - 19:18, 30 August 2024